Merck puts money on Arcoxia
Executive Summary
Merck raises 2007 earnings guidance on the assumption that Arcoxia (etoricoxib), its follow-on product to the withdrawn arthritis medication Vioxx, will be approved by FDA, the company announces Dec. 6. The Arcoxia NDA has a user fee action date in April 2007 following Merck's submission of a response to FDA's November 2004 "approvable" letter (1"The Pink Sheet" Nov. 13, 2006, In Brief). The submission limits the proposed indication for the COX-2 inhibitor, which has been approvable since October 2004, to osteoarthritis. Merck anticipates that 2007 earnings per share will be in the range of $2.36 to $2.49. "Other sales," which includes products Arcoxia, Januvia and Proscar among many others, is expected to be between $5.2 billion and $5.6 bil...
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.